The lead investigator of the largest clinical trial program in people with CAH discusses the condition, its burden, and the novel drug just approved that will change lives.
Richard J Auchus, MD, PhD
Advertisement
Articles by Richard J Auchus, MD, PhD
Auchus details findings from the unique study of the CRF-1 antagonist crinecerfont, the first new therapy for CAH approved in 70 years.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Patient Care Online
1
New Menopause Survey Finds Energy Loss, Poor Sleep, and Seasonal Symptoms Most Disruptive
2
The Adult Immunization Catch-Up Schedule: A Practical Guide for Primary Care
3
Undertreated Acute Pain Poses Long-Term Risks, But Prescription Opioids Still Do, Too ...
4
Diagnosing DVT: Clinical Pearls for Challenging Presentations
5
